As of May 2013
Research Education Updates:
Research Cancer Immunotherapy
Learn more about the potential of PD-L1 inhibition and cancer immunotherapy.
Updated the site to include more information about Glycoengineering.
Pipeline Molecules Updates:
Pipeline Overview: Content Update
For more information about molecules in early-and late stage development download the new brochure.
Anti-PDL1 targets, a protein expressed on the surface of cancer cells. Find out how this molecule was designed to help promote anti-tumor immune activity.
Anti-CD22 ADC (DCDT2980S)
The Anti-CD22 ADC is composed of a MAb, a stable linker, and a cytotoxic. Find out how this molecule may selectively target B-cells expressing CD22.
Anti-CD79b ADC (DCDS4501A)
The Anti-CD79b ADC is composed of a MAb, a stable linker, and a cytotoxic. Find out how this molecule may selectively bind to CD79b and minimize effects on normal cells.
Therapeutic Targets Updates:
Learn more about CD22, a cell surface protein that is only expressed on B-cells.
Find out about CD79b, a key component of the B-cell receptor, and its role in malignant B-cell signaling.
Updated Video Narrations:
Biological Pathways: HER signaling: Updated Video
Biological Pathways: Apoptotic pathways: Updated Video
Biological Pathways: MAPK signaling: Updated Video
Biological Pathways: PI3K signaling: Updated Video
Biological Pathways: Angiogenic signaling: Updated Video
As of December 2012
Anti-HER3/EGFR MAb (MEHD7945A) was added to the Genentech Pipeline.